Prognostic Factors in Acute Myeloid Leukemia

Demographic and Epidemiologic Factors

• Age is the single most powerful patient‑related prognostic factor, independently predicting both treatment‑related mortality and disease outcomes. Evidence level: not specified. 1
• The median age at AML diagnosis is 67–71 years. Evidence level: not specified. 2
• Patients aged ≥ 75 years represent roughly one‑third of all AML diagnoses and have a markedly poor prognosis. Evidence level: not specified. 2
• AML‑related mortality in the general population is approximately 4–6 deaths per 100,000 persons per year. Evidence level: not specified. [3][4]
• An estimated 10,900 AML deaths occur annually in the United States. Evidence level: not specified. 2

Cytogenetic Risk Stratification

• Cytogenetic abnormalities are the strongest predictor of response to induction therapy and overall survival. Evidence level: not specified. 1

Favorable‑Risk Cytogenetics

• t(15;17)(q22;q21) / PML‑RARA (acute promyelocytic leukemia) yields an approximate 70 % cure rate with all‑trans retinoic acid‑based therapy. Evidence level: not specified. 5
• t(8;21)(q22;q22) / RUNX1‑RUNX1T1 defines core‑binding‑factor AML with favorable prognosis. Evidence level: not specified. 1
• inv(16)(p13.1q22) or t(16;16)(p13.1;q22) / CBFB‑MYH11 defines core‑binding‑factor AML with myelomonocytic differentiation and favorable outcome. Evidence level: not specified. 1

Intermediate‑Risk Cytogenetics

• Cytogenetically normal AML lacking favorable molecular markers falls into the intermediate‑risk category. Evidence level: not specified. 1
• t(9;11)(p22;q23) / MLLT3‑MLL is classified as intermediate risk. Evidence level: not specified. 6
• Isolated trisomy 8 is considered intermediate risk. Evidence level: not specified. 1

Adverse‑Risk Cytogenetics

• Complex karyotype (≥ 3 unrelated chromosomal abnormalities) occurs in 10–12 % of patients and is consistently associated with very poor outcomes. Evidence level: not specified. 1
• Monosomy 5 or deletion 5q predicts adverse prognosis. Evidence level: not specified. 1
• Monosomy 7 or deletion 7q predicts adverse prognosis. Evidence level: not specified. 1
• t(6;9)(p23;q34) / DEK‑NUP214 is an adverse‑risk abnormality. Evidence level: not specified. 1
• Other MLL rearrangements (excluding t(9;11)) are adverse‑risk lesions. Evidence level: not specified. 1

Molecular Genetic Refinement (Cytogenetically Normal AML)

• NPM1 mutation without FLT3‑ITD, or with FLT3‑ITD allelic ratio < 0.5, confers a favorable prognosis. Evidence level: not specified. 6
• Biallelic CEBPA mutations are associated with favorable outcomes. Evidence level: not specified. 6
• FLT3‑ITD with a high mutant allele burden (≥ 0.5) predicts a high and early relapse rate. Evidence level: not specified. 6
• TP53 mutations, frequently co‑occurring with complex karyotype, confer the worst prognosis. Evidence level: not specified. 1

Therapy‑Related and Secondary AML

• Therapy‑related AML (t‑AML) and AML evolving from prior myelodysplastic syndrome carry uniformly poor prognosis. Evidence level: not specified. [2][7]
• t‑AML accounts for 5–20 % of all AML cases. Evidence level: not specified. [2][7]
• t‑AML is associated with prior exposure to alkylating agents, topoisomerase inhibitors, or radiotherapy. Evidence level: not specified. [2][7]
• The disease course of t‑AML is generally progressive and more resistant to conventional cytotoxic therapies than de novo AML. Evidence level: not specified. [2][7]

Treatment Response and Remission

• Intermediate‑ and adverse‑risk patients have lower complete remission (CR) rates and often require allogeneic stem‑cell transplantation for cure. Evidence level: not specified. 3

Additional Prognostic Pitfalls

• Elevated white‑blood‑cell count at presentation is associated with worse outcomes. Evidence level: not specified. 1
• Poor performance status and comorbidities predict higher treatment‑related mortality, especially in elderly patients. Evidence level: not specified. [3][6]
• Failure to achieve CR after two induction cycles should reclassify patients as adverse‑risk regardless of initial genetic profile. Evidence level: not specified. 1

Minimal Residual Disease (MRD) Monitoring

• Flow‑cytometry‑based MRD assessment is increasingly employed, particularly in favorable‑risk subgroups, providing independent prognostic information beyond initial risk stratification. Evidence level: not specified. 5

AML Prognosis

Risk Stratification Framework

• The prognosis of AML is highly heterogeneous and primarily determined by cytogenetic abnormalities, molecular mutations, patient age, and treatment response, with overall 5-year survival ranging from >70% in favorable-risk pediatric patients to <23% in adverse-risk adults 8, 9
• Cytogenetics represent the most powerful predictor of response to induction therapy and survival, with favorable risk cytogenetics including t(8;21)(q22;q22)/RUNX1-RUNX1T1, inv(16)(p13.1q22)/CBFB-MYH11, and t(15;17)(q22;q21)/PML-RARA 8, 9, 10, 11, 12
• Intermediate risk cytogenetics include cytogenetically normal AML without favorable molecular markers, and t(9;11)(p22;q23)/MLLT3-MLL 8, 9, 11
• Adverse risk cytogenetics include complex karyotype, monosomy 5, deletion 5q, monosomy 7, inv(3)(q21q26.2) or t(3;3)(q21;q26.2)/RPN1-EVI1, and t(6;9)(p23;q34)/DEK-NUP214 8, 9, 10, 11, 12, 13, 14

Molecular Genetic Refinement

• Within cytogenetically normal AML, molecular mutations critically refine prognosis, with favorable molecular markers including NPM1 mutation without FLT3-ITD, and biallelic CEBPA mutations 9
• Adverse molecular markers include FLT3-ITD, particularly with high mutant allele burden, KIT mutations in CBF-AML, and WT1, RUNX1, ASXL1, DNMT3A mutations 9

Patient-Related Prognostic Factors

• Age is the single most important patient-related adverse prognostic factor, independent of disease biology, with younger adults (18-60 years) having 30-40% 5-year survival, and older adults (>60 years) having significantly worse outcomes 8, 9, 10, 11, 13
• Pediatric patients (<18 years) have 60-75% 5-year survival 11, 12
• Secondary AML (following MDS or prior cytotoxic therapy) carries uniformly poor prognosis, with therapy-related AML (t-AML) remaining an independent adverse prognostic factor even after adjusting for cytogenetics 8, 10, 15

Treatment Response as Prognostic Indicator

• Treatment response assessment after induction therapy is recommended for risk stratification, with complete remission (CR) rates varying by risk group and treatment intensity 12, 14
• Minimal residual disease (MRD) monitoring provides independent prognostic information, particularly in favorable-risk subgroups 9, 12

Relapsed/Refractory Disease Prognosis

• Relapsed AML carries extremely poor prognosis, stratified by a validated prognostic index, with favorable relapse risk having 1-year survival 70%, and 5-year survival 46% 15
• Key relapse risk factors include duration of first remission (<6 months worst), cytogenetics at diagnosis, prior HSCT, and age at relapse 15